UNSPSC 51391614: Isometheptene hydrochloride

This classification denotes an adrenergic agent with the molecular formula C9H19N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9Z4CJC3O5F, chemically known as 5-hepten-2-amine, n,6-dimethyl-, hydrochloride but more generally known as isometheptene hydrochloride, which bears US NIH Compound Identifier 22297. European Medicines Agency schedules Isometheptene hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14276MIG.

Most nations, for tariff and trade purposes, schedule isometheptene hydrochloride under HS 29211980 and SITC 51451. As of Q4 2014, ISOMETHEPTENE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Isometheptene hydrochloride bears US NLM identifiers UMLS ID C2697822 and NCI Concept Code C80003. SMILES: CC(CCC=C(C)C)NC.CL.

UNSPSC 51391614 Isometheptene hydrochloride is a Commodity code that nominally names a single active pharmaceutical ingredient, but recent state and local solicitations tagged under it reflect a broader scope: procurement of pharmaceutical products and related health systems for community health and pharmacy benefit programs. The work being solicited includes the purchase of finished pharmaceutical products (naloxone for opioid overdose response and drug deactivation systems) and the establishment of direct contracting relationships between state pharmacy programs and manufacturers to optimize prescription fulfillment and cost management. Issuing bodies span county health departments and state health and human services agencies, reflecting both local emergency-response procurement and statewide pharmacy-benefit contracting activity.

Activity is concentrated in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, bidding deadline July 26, 2023, with vendors required to include shipping and delivery costs and maintain workers' compensation, commercial general liability, and professional liability insurance; the contract includes a two-year initial term with one-year renewal option and potential FEMA funding. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor information on direct-to-manufacturer prescription contracting capabilities for self-insured employer and state agency health plans, with no formal evaluation criteria or award value specified at this exploratory stage. Both opportunities target vendors with pharmaceutical supply-chain and contracting experience; neither specifies set-aside designations for disadvantaged enterprises.